Loading...
Loading...
India's bisacodyl imports from JAPAN total $169 across 6 shipments from 2 foreign suppliers. SSP CO LTD leads with $98 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include SANOFI HEALTHCARE INDIA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for bisacodyl โ a concentrated sourcing relationship with select suppliers from JAPAN.

SSP CO LTD is the leading Bisacodyl supplier from JAPAN to India, with import value of $98 across 3 shipments. The top 5 suppliers โ SSP CO LTD, SSP CO LIMITED โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SSP CO LTD | $98 | 3 | 57.9% |
| 2 | SSP CO LIMITED | $71 | 3 | 42.1% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | SANOFI HEALTHCARE INDIA PRIVATE LIMITED | $169 | 6 | 100.0% |
JAPAN โ India trade corridor intelligence
The Japan to India shipping corridor has experienced stable transit times, with sea freight averaging 7 days and air freight around 3 days. Both modes account for approximately 50% of the shipments. Port congestion at major Indian ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra has been minimal, ensuring timely deliveries. Freight rates have remained consistent, and the exchange rate between the Japanese Yen and Indian Rupee has been favorable for Japanese exporters.
The PLI scheme introduced by the Indian government aims to reduce import dependency by promoting domestic manufacturing of pharmaceutical products, including Bisacodyl formulations. This policy encourages foreign manufacturers to set up production facilities in India, thereby decreasing the need for imports.
India and Japan maintain strong trade relations, with ongoing discussions to enhance cooperation in various sectors, including pharmaceuticals. However, no specific Free Trade Agreements (FTAs) or mutual Good Manufacturing Practice (GMP) recognition agreements have been established between the two countries during the 2024-2026 period.
The landed cost of importing Bisacodyl formulations from Japan to India includes the following components:
The total landed duty percentage is approximately 20%, excluding IGST and other charges.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Bisacodyl into India, the importing company must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves registering both the manufacturing site and the specific product. The application is submitted to the Drugs Controller General (I) at CDSCO, accompanied by necessary documents such as the manufacturing license, Good Manufacturing Practice (GMP) certificate, and Certificate of Pharmaceutical Product (COPP). The registration certificate is valid for three years and must be renewed nine months before expiration.
Additionally, an Import License is required for each consignment. This license is issued by CDSCO upon verification of the registration certificate and other compliance documents.
Imported pharmaceutical formulations containing Bisacodyl must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, is essential to demonstrate the product's shelf-life under India's climatic conditions. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the imported goods.
Between 2024 and 2026, the Indian government has implemented the Production Linked Incentive (PLI) scheme to encourage domestic manufacturing of pharmaceutical products, including formulations containing Bisacodyl. This initiative aims to reduce import dependency and boost local production. However, no significant bilateral agreements with Japan have been established during this period to facilitate pharmaceutical imports.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished Bisacodyl formulations primarily due to the demand for branded products, specific dosage forms, and formulations not produced domestically. The market size for Bisacodyl formulations in India is substantial, with a total export market of $8.6 million across 240 exporters to 108 countries.
The Basic Customs Duty (BCD) for Bisacodyl formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is applicable as per the prevailing GST rates.
India sources Bisacodyl formulations from Japan due to the high quality, advanced manufacturing technologies, and adherence to international standards. Japanese manufacturers offer specialized dosage forms and formulations that may not be available domestically. While other countries like China, Germany, and the United States also supply Bisacodyl formulations, Japan's reputation for quality and innovation provides a competitive advantage.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Bisacodyl formulations from Japan due to the availability of patented or branded products, specialized dosage forms, and formulations not produced domestically. Japanese manufacturers offer high-quality products that meet international standards, which are essential for the Indian market.
Compared to other sources like China, the European Union, and the United States, Japan offers superior quality, advanced manufacturing technologies, and adherence to international standards. While other countries may provide lower-priced alternatives, Japan's reputation for quality and reliability makes it a preferred choice for importing Bisacodyl formulations.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, it is advisable to diversify suppliers, maintain adequate inventory levels, and establish strong relationships with reliable partners.
Import license checklist, document requirements, quality testing, and compliance
Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the imported goods. Mandatory batch testing is conducted, including sample collection and analysis. Timelines for testing vary, and if a batch fails, it may be rejected or destroyed. Common quality issues from Japanese imports include discrepancies in labeling and packaging.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Bisacodyl suppliers from JAPAN to India include SSP CO LTD, SSP CO LIMITED. The leading supplier is SSP CO LTD with import value of $98 USD across 3 shipments. India imported Bisacodyl worth $169 USD from JAPAN in total across 6 shipments.
India imported Bisacodyl worth $169 USD from JAPAN across 6 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Bisacodyl sourced from JAPAN include SANOFI HEALTHCARE INDIA PRIVATE LIMITED. The largest buyer is SANOFI HEALTHCARE INDIA PRIVATE LIMITED with $169 in imports across 6 shipments.
The total value of Bisacodyl imports from JAPAN to India is $169 USD, across 6 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
6 Verified Shipments
2 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists